# IQVIA Research Forum 2022

Pathways and Priorities for High Impact Health Research

October 2022

IQVIA Institute for Human Data Science contributes to advancing human health by generating rigorous, evidence-based research

PROPRIETARY DATA SOURCES*

SUBJECT MATTER EXPERTS

ADVANCED ANALYTICAL SKILLS

THIRD PARTY INFORMATION

ACADEMIC PARTNERS

EXTERNAL EXPERTS

EVIDENCE-BASED RESEARCH

IQVIA INSTITUTE FOR HUMAN DATA SCIENCE

OBJECTIVE INTER-PRETATION

HEALTH SYSTEM PERSPECTIVE

LIBRARY OF REPORTS

CONFERENCES AND FORUMS

PEER-REVIEWED RESEARCH

PRESS AND SOCIAL MEDIA ENGAGEMENT

*No confidential sponsor or customer data is accessible or used

IQVIA INSTITUTE

Support for academic researchers

How researchers can benefit from IQVIA data

Through collaboration with the IQVIA Institute, researchers have access to a broad range of proprietary databases and tools to support independent research, discovery work, and requirement development for future funded studies.

Collaborating with the IQVIA Institute

Researchers interested in collaborating with the IQVIA Institute on specific research studies should contact us at **info@iqviainstitute.org.**

Detailed information is available on our web site at **iqviainstitute.org** under Research Support.

IQVIA data assets frequently used in academic research

1 **Formulary Impact Analyzer:** Pharmacy claims with insight into paid, rejected or reversed adjudication status.

2 **Longitudinal Prescription Claims (LRx):** Prescription claims from retail, mail and long-term care pharmacies.

3 **Medical and Institutional Claims (Dx and Hx):** Unadjudicated office and institutional medical claims.

4 **MIDAS:** Global pharmaceutical sales at a country and therapeutic level.

5 **National Prescription Audit (NPA):** Nationally projected prescription volume from retail, mail and long-term care pharmacies.

6 **National Sales Perspectives (NSP):** Nationally projected ship-to transaction volume and revenue to all retail and non-retail entities.

7 **OneKey:** Comprehensive healthcare organizational and professional affiliation data.

8 **Pharmetrics Plus for Academics:** Longitudinal health plan data for adjudicated claims.

IQVIA INSTITUTE

Pathways and Priorities for High Impact Health Research

IQVIA Research Forum 2022

Exploring the elusive nature of applied research in national health crises

How to improve the effectiveness of critical health research?

Monday, Oct 10
10 - 11 a.m.

Incorporating the impact of social determinants on outcomes in healthcare research

What are the considerations for the broader use of social determinants in research?

Monday, Oct 10
11 a.m. - 12 p.m.

Navigating the complexity and heterogeneity of patient affordability and access

What do affordability and access mean in a diverse population?

Tuesday, Oct 11
10 - 11 a.m.

Elevating the value to patients of academic health research

What research strategies can achieve increased value to patients?

Wednesday, Oct 12
10 - 11 a.m.

Charting the future of high impact health research

How to raise the ongoing value of health research?

Wednesday, Oct 12
11 a.m. – 12 p.m.

IQVIA INSTITUTE

Navigating the complexity and heterogeneity of patient affordability and access

What do affordability and access mean in a diverse population?

Framing some high-level questions for our panelists

Defining affordability – the 'to whom' question

If we don't know what it is, how do we measure if we're addressing it?

What evidence is critical in evaluating affordability and access to innovation?

What policies are effective in increasing access to affordable healthcare?

How can research provide support to advance similar policies?

What issues are confounding efforts to increase access to affordable healthcare?

IQVIA INSTITUTE

Over 92% of prescriptions have a final out-of-pocket cost below $20, 1% (64 million) prescriptions have costs above $125

*Distribution of prescriptions by out-of-pocket cost in 2021, all channels*

All prescriptions: brands and generics — 92% ... 1%
Brands only — 73% ... 4%

Categories (All payers, Commercial, Medicare, Medicaid, Cash/assistance)

Legend:
- $500+
- $250-$499.99
- $125-$249.99
- $75-$124.99
- $50-$74.99
- $40-$49.99
- $30-$39.99
- $20-$29.99
- $10-$19.99
- $0.01-$9.99
- $0

IQVIA INSTITUTE

Overall, 8% of patients reach annual out-of-pocket costs above $500 compared to 16% in Medicare largely due to benefit design

*Patients by annual prescription out-of-pocket cost in 2021*

All payers
29%
8%
234Mn

Medicare
22%
16%
42Mn

Commercial
23%
7%
113Mn

Medicaid
74%
<1%
37Mn

Legend:
- $1,500+
- $1,250-$1,499.99
- $1,000-$1,249.99
- $750-$999.99
- $500-$749.99
- $400-$499.99
- $300-$399.99
- $200-$299.99
- $100-$199.99
- $50-$99.99
- $1-$49.99
- $0

X-axis: 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%

IQVIA INSTITUTE
FOR HUMAN DATA SCIENCE

7

Patients of diverse racial and ethnic backgrounds are experiencing cost in the health system differently

Fewer non-White patients use copay cards, but users are more exposed to CAP programs

Difference in Likelihood of Copay Card Use and CAP Exposure, Non-White Patients, Adjusted
(Ref: White; Commercial patients only; Jan 2019 – Sep 2021)

Non-White patients are about as likely to use copay cards than White patients, after controlling for other factors

-0.5%

Copay Card Use*

But among the copay cards users, non-White patients are 31% and 27% **_more_** likely to be exposed to accumulators and maximizers, respectively, after controlling for other factors

30.8%*

27.4%*

Accumulator   Maximizer

Source: JMCP Nexxus 2022 Poster Abstracts: https://www.jmcp.org/doi/abs/10.18553/jmcp.2022.28.10-a.s1

Source: US Market Access Strategy Consulting analysis, * indicates a significant p-value (<.05);

IQVIA INSTITUTE

Today's panelists

Ernst (Ernie) Berndt, Ph.D.
Professor, Applied Economics
MIT Sloan School of Management

Stacie Dusetzina, Ph.D.
Associate Professor, Health Policy
Vanderbilt University Medical Center

Richard Frank, Ph.D.
Senior Fellow, Economic Studies
The Brookings Institution

Rena Conti, Ph.D.
Associate Professor, Markets, Public
Policy and Law
Boston University Questrom School of
Business

Moderator: Michael Kleinrock, Research Director, IQVIA Institute

IQVIA
INSTITUTE

Q&A

Post your questions and comments in the Q&A box

2022 Research Forum Agenda

Exploring the elusive nature of applied research in national health crises

How to improve the effectiveness of critical health research?

Monday, Oct 10
10 - 11 a.m.

Incorporating the impact of social determinants on outcomes in healthcare research

What are the considerations for the broader use of social determinants in research?

Monday, Oct 10
11 a.m. - 12 p.m.

Navigating the complexity and heterogeneity of patient affordability and access

What do affordability and access mean in a diverse population?

Tuesday, Oct 11
10 - 11 a.m.

Elevating the value to patients of academic health research

What research strategies can achieve increased value to patients?

Wednesday, Oct 12
10 - 11 a.m.

Charting the future of high impact health research

How to raise the ongoing value of health research?

Wednesday, Oct 12
11 a.m. – 12 p.m.

IQVIA INSTITUTE

# Download featured Institute content

www.IQVIAInstitute.org

Find us on social media

Twitter: @IQVIA_Institute

LinkedIn: #IQVIAInstitute

Thank you